Context

GENSIGHT is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

GENSIGHT’s pipeline leverages two core technology platforms: Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases.

The company’s lead product candidate, GS010 (LUMEVOQ), is in Phase III trials for Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible vision loss in teens and young adults. GenSight is well positioned to capitalize on addressing LHON as the first gene therapy (GTx) for the condition, and only the fifth potentially approved gene therapy. GENSIGHT recently submitted a European Marketing Authorization Application for LUMEVOQ in Europe.

Follow-on Offering proceeds will be mainly used to actively prepare the commercial launch of LUMEVOQ in Europe and finance the end of the clinical development necessary for the filing of a Biologics License Application (BLA) in the US; and to prepare a Phase III clinical trial of GS030 for the treatment of Retinitis Pigmentosa.

Tombstone_gensight

About GenSight

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

Discover GenSight

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Hervé Ronin

Investment Banking

Hervé Ronin photo

Vincent Meunier

Investment Banking

Vincent Meunier photo

Mickael Dubourd

Investment Banking

Mickael Dubourd photo

Cosme Rosellini

Equity Capital Markets

Cosme Rosellini photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center